List of Singulair drug patents

Singulair is owned by Organon.

Singulair contains Montelukast Sodium.

Singulair has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Singulair are:

  • US8007830

Singulair was authorised for market use on 26 July, 2002.

Singulair is available in granule;oral dosage forms.

The generics of Singulair are possible to be released after 24 October, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007830 ORGANON Granule formation
Oct, 2022

(3 months ago)

Drugs and Companies using MONTELUKAST SODIUM ingredient

Market Authorisation Date: 26 July, 2002

Treatment: NA

Dosage: GRANULE;ORAL

How can I launch a generic of SINGULAIR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in